Optimizing cardiovascular risk reduction during antihypertensive therapy.

Weinberger, Myron H.

doi:10.1161/01.hyp.16.2.201

Cited by 9 publications

(2 citation statements)

References 92 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…During this study, the administration of quinapril alone or in combination did not affect lipids and lipoproteins. On the other hand, as reported previously (Weinberger, 1990), atenolol induced a significant rise in triglyceride levels that became greater with addition of the diuretic. Even though the status of hypertriglyceridaemia remains controversial (Brunzell & Austin, 1989), our findings may be relevant since in certain circumstances, elevated triglyceride levels may be a risk factor for coronary heart disease (Austin 1991;Castelli, 1986).…”

Section: Discussionsupporting

confidence: 85%

Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.

Lacourcière

Lefèbvre

Provencher

et al. 1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 85%

Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.

Lacourcière

Lefèbvre

Provencher

et al. 1993

Brit J Clinical Pharma

View full text Add to dashboard Cite

“…Low-dose combinations of angiotensin-converting enzyme (ACE) + diuretic have recently been introduced to maintain antihypertensive efficacy with fewer adverse metabolic effects. [5][6][7] A fixed low-dose perindopril 2 mg/indapamide 0.625 mg (Per 2/Ind 0.625) combination have recently been developed. Regarding the pharmacokinetic characteristics of each component, their similar half-life justifies the perindopril-indapamide combination with a posology of one tablet per day.…”

mentioning

confidence: 99%

Fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination in very elderly hypertensives

Forette

1999

J Hum Hypertens

View full text Add to dashboard Cite

Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma Lipoproteins

Lacourcière

Poirier

Lefèbvre

et al. 1992

The Journal of Clinical Pharma

View full text Add to dashboard Cite

This double-blind, parallel-group study compared the effects of nebivolol, a novel cardioselective beta-blocker, with those of nifedipine sustained-release on 24-hour ambulatory blood pressure and plasma lipoprotein levels. After a washout period of 8 weeks, 51 patients with mild to moderate essential hypertension were randomized to double-blind treatment with either nebivolol 5 mg once a day (n = 26) or nifedipine sustained-release 20 mg bid (n = 25) over a period of 12 weeks. Both treatments produced similar and significant (P = .0001) reduction in office blood pressure as well as in 24-hour, work, awake, and sleep ambulatory blood pressure. The clinical response (diastolic blood pressure less than 90 mmHg or decreased by greater than or equal to 10 mmHg) rate was 69% for nebivolol and 59% for nifedipine, respectively. Moreover, the nebivolol and nifedipine treatment-induced decreases in mean 24-hour ambulatory blood pressure were similar to the decreases in clinic blood pressure. Furthermore, the percentages of "blood pressure loads" (awake greater than 140/90 mmHg and asleep greater than 120/80 mmHg) were lowered significantly (P = .0001), from 60% to 29% with nebivolol and from 60% to 39% with nifedipine. Mean ambulatory heart rate was reduced (P = .0001) from 79 +/- 7 to 68 +/- 7 beats/minute during nebivolol therapy and from 80 +/- 9 to 79 +/- 7 (not significant) with nifedipine. Total plasma cholesterol and low-density lipoprotein levels decreased significantly (P less than .05) by 5 and 8%, respectively, after nebivolol treatment, and each decreased by 3% after nifedipine treatment.(ABSTRACT TRUNCATED AT 250 WORDS)

show abstract

Optimizing cardiovascular risk reduction during antihypertensive therapy.

Cited by 9 publications

References 92 publications

Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.

Comparison of quinapril and atenolol as single drugs or in combination with hydrochlorothiazide in moderate to severe hypertensives, using automated ambulatory monitoring.

Fixed low-dose perindopril 2 mg/indapamide 0.625 mg combination in very elderly hypertensives

Comparative Effects of a New Cardioselective Beta‐Blocker Nebivolol and Nifedipine Sustained‐Release on 24‐Hour Ambulatory Blood Pressure and Plasma Lipoproteins

Contact Info

Product

Resources

About